What is the lead time for production?

The average lead time is one month for both peak and off-season.

What payment terms are accepted?

Payment terms include T/T, Western Union, and small-amount payment.

How is the quality controlled?

There are 5 QA/QC inspectors performing random visual and functional inspections.

Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide

Name: Hhd Pharm Livagen (Lys-Glu-Asp-Ala) Weakly Hydrolyzed Peptide
Brand: Wuhan Hengheda Pharm Co., Ltd.
SKU: 1917004551

Hubei, ChinaWuhan Hengheda Pharm Co., Ltd.

US$5.00-10.00

1 grams

Product profile

Customization

Available

Transport Package

Al-Foil Bag

Specification

1bags

Model NO.

Livagen (Lys-Glu-Asp-Ala)

Trademark

HHD

Origin

China

Production Capacity

1000bags

Key features

GMP & ISO Certified: Certified under GMP and ISO 9001 for quality assurance.

Multi-Demographic Use: Suitable for elderly, children, and adults.

Scientific Mechanism: Activates ribosomal genes and decondenses heterochromatin in chromosomes.

Strong Efficacy: More efficient than puromycin, leupeptin, and D-PAM with IC50 of 20 microM.

Full Customization: Offers full customization and sample-based customization options.

Established Manufacturer: 15 years of export experience with 2 production lines.

Strict Quality Control: 5 QA/QC inspectors ensure random visual and functional inspection.

Company profile

Importers and ExportersFull CustomizationODM ServicesQuality Assurance

Wuhan Hengheda Pharm Co., Ltd.

Hubei, China

Business Type: Manufacturer/Factory, Trading Company CertifiedR&D Capacity: ODM Service Available CertifiedCustomization Options: Customization from Samples, Full Customization CertifiedExport Year: 15 Years CertifiedNearest Port: Shanghai PortAverage Response Time: ≤7.87h

AI-Powered supplier vetting

SummaryWuhan Hengheda Pharm Co., Ltd. is a China-based limited manufacturing company established in 2013, with 27 employees and operations in Hubei. It specializes in pharmaceutical intermediates, APIs, fine chemicals, natural extracts, food additives, health-related products, custom synthesis, and related OEM services. The supplier reports a 1,000-square-meter R&D and pilot-scale platform, three production lines, and a cooperative production base with 50L–2,000L reaction vessels and tonnage-level R&D and production capacity. It exports 41%–50% of total sales and began exporting in 2012. An SGS audit is recorded, but the audit result is coded as 0 and the stated validity period ended on 2025-07-21; the meaning of the result code is not provided. Most service, quality-system, customer-case, and certification details remain unknown, so several fields cannot be conclusively assessed.

Supplier typeThe supplier is identified as Wuhan Hengheda Pharm Co., Ltd., a Chinese limited company and factory located in Hubei. Its stated business focuses on custom synthesis, manufacture, and import/export of fine chemicals, APIs, and pharmaceutical intermediates.

R&D capabilityThe supplier reports a 1,000-square-meter R&D and pilot-scale platform with modern experimental equipment and the ability to conduct small-scale research and pilot production of compounds. The records also state two years of R&D engineer experience, but product-launch, ODM, SDK, and other innovation indicators are unknown.

Production capacityThe supplier reports three production lines and a cooperative production base exceeding 30 mu, equipped with stainless-steel and glass-lined vessels ranging from 50L to 2,000L. It states that the base supports tonnage-level R&D and production, providing explicit evidence of substantial production infrastructure.

Customization capabilityCustom synthesis is listed among the supplier's primary offerings, and the company describes R&D and pilot-scale capabilities for producing various compounds. These statements directly support customization for chemical and pharmaceutical-related products, although specific project examples and service procedures are not provided.